Drugs.com - New Drug Approvals

FDA Approves Attruby (acoramidis) to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM

PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical company focused on genetic diseases, today announced that the U.S. Food and Drug...

Feb 9, 2025 - 21:45
 0
FDA Approves Attruby (acoramidis) to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM
PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical company focused on genetic diseases, today announced that the U.S. Food and Drug...
Read More

Tags:

Previous Article

FDA Approves Simplified Dosing Regimen for Acetadote (N-acetylcysteine for injec...

Next Article

Weight Gain Common in Young Women After Breast Reduction Surgery

Related Posts

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for...

Feb 9, 2025  0

FDA Approves Merilog (insulin-aspart-szjj), a Biosimilar to NovoLog

FDA Approves Merilog (insulin-aspart-szjj), a Biosimila...

Feb 18, 2025  0

Rhythm Pharmaceuticals Announces FDA Approval of Imcivree (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces FDA Approval of Imcivr...

Feb 9, 2025  0